Results for HS-410 Vaccine in Non-Muscle Invasive Bladder Cancer

May 22, 2017

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer.